Phase 3 N=87 Gammagard Liquid and rHuPH20 in PID
Primary Immunodeficiency Diseases (PID)
Primary: Validated Acute Serious Bacterial Infection (VASBI) Rate — 0.025 Estimated infections/year — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=93 Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events
Stroke · Myocardial Infarctions
Primary: PFA1 — 202.0; 271.1; 234.7 seconds — p=0.0742
Phase 3 N=155 Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly
Acromegaly
Primary: Percentage of Responders at the End of the Core Treatment Period — 86.9; 66.7; 40.4; 64.9 Percentage of responders
Phase 3 N=97 Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia
Schizophrenia
Primary: Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score — -22.9; -19.4 Units on a scale — p=<0.0001
Phase 3 N=142 A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase
Dementia With Lewy Bodies (DLB)
Primary: Change From Baseline in Mini-Mental State Examination (MMSE) Score — 0.6; 1.4; 2.2 Units on a scale
Phase 3 N=272 Phase III Study of ICI35,868 (Diprivan) With and Without EES0000645/A (SDS) on Gastrointestinal Endoscopy
Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy
Primary: Achivement of Target Sedation — 21.6; 88.1; 94.5 % of patients — p=<0.001
Phase 3 N=41 A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Primary: Coefficient of Fat Absorption (CFA) — 88.1; 89.5 percentage of fat intake
Phase 3 N=4,110 Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Chronic Kidney Disease · Cardiovascular Disease · Death
Primary: Recurrent or de Novo Arteriosclerotic Cardiovascular Disease (CVD) Defined as the Occurrence of Non-fatal or Fatal Arteriosclerotic Outcomes Including Coronary Heart…
Phase 3 N=200 A Study of Fluoxetine in Major Depressive Disorder (MDD) Long-Term Dosing
Major Depressive Disorder
Primary: Number of Participants With Adverse Events (AEs) or Serious AEs (SAEs) — 2; 1; 0; 75 participants
Phase 3 N=824 Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
Depressive Disorder · Depression · Depressive Disorder, Major
Primary: Change From Baseline (End of Phase A [Week 8]) to Week 14 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score for the Efficacy Sample. — -8.27; -5.15 Units…
Phase 3 N=167 A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer
Premenopausal Breast Cancer
Primary: Percentage of Participants With Suppressive Effect of Serum Estradiol (E2) to Menopausal Level (=<30 pg/mL) From Week 4 Through Week 48 — 97.6; 96.4 percentage of…
Phase 3 N=413 Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin
Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin) — 0.10; -0.74; -0.39 percentage of glycosylated haemoglobin
Phase 3 N=242 Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects
Obesity · Overweight
Primary: Percent Change in Body Weight From Baseline (Day 1) to Week 26 — -9.46; -0.94 percent change in body weight — p=<0.0001
Phase 3 N=598 Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Overall Survival — 26.81; 24.97 months — p=0.831
Phase 3 N=332 A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy
Colorectal Cancer Metastatic
Primary: Progression-free Survival (PFS) — 5.59; 6.93 months